Cargando…

Combining PARP and CDK4/6 inhibitors in MYC driven ovarian cancer

Detalles Bibliográficos
Autor principal:	Konecny, Gottfried E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557782/ https://www.ncbi.nlm.nih.gov/pubmed/30979685 http://dx.doi.org/10.1016/j.ebiom.2019.04.009

Ejemplares similares

Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer
por: Zhu, Xiuzhi, et al.
Publicado: (2021)

Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?
por: Ray-Coquard, Isabelle, et al.
Publicado: (2020)

PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer
por: Wu, Cheng, et al.
Publicado: (2021)

PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
por: Konecny, G E, et al.
Publicado: (2016)

Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
por: Bolin, Sara, et al.
Publicado: (2018)

Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma
por: Ning, Jian-Fang, et al.
Publicado: (2019)

Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
por: Bonadio, Renata Colombo, et al.
Publicado: (2021)

Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?
por: Batista, Thales Paulo, et al.
Publicado: (2020)

KIAA1529 regulates RAD51 expression to confer PARP inhibitors resistance in ovarian cancer
por: Qiao, Yuan, et al.
Publicado: (2022)

The role of PARP inhibitor combination therapy in ovarian cancer
por: Hockings, Helen, et al.
Publicado: (2023)

Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review
por: Nur Husna, Siti Muhamad, et al.
Publicado: (2018)

Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer
por: Hashimoto, Ari, et al.
Publicado: (2021)

PARP inhibitors are not all equal
por: Dent, Paul
Publicado: (2013)

PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies
por: Miller, Rowan E, et al.
Publicado: (2022)

PARP inhibitors in ovarian cancer
por: Cibula, David, et al.
Publicado: (2015)

MBRS-19. SYNERGISM OF HDAC AND PARP INHIBITORS IN MYC-DRIVEN GROUP 3 MEDULLOBLASTOMA CELLS
por: Vollmer, Johanna, et al.
Publicado: (2020)

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
por: Kim, Hyoung, et al.
Publicado: (2020)

Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
por: Zeng, Mei, et al.
Publicado: (2018)

Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer
por: Tang, Bin, et al.
Publicado: (2023)

Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation
por: Quan, Chuntao, et al.
Publicado: (2023)

Oxygen-independent, CDK4/CDK6-dependent degradation of hypoxia-inducible factor-1α takes cancers’ breath away
por: Neckers, Len
Publicado: (2022)

Efficacy of combined targeted therapy with PI3K and CDK4/6 or PARP and WEE1 inhibitors in neuroblastoma cell lines
por: Lukoseviciute, Monika, et al.
Publicado: (2023)

Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2− Metastatic Breast Cancer: A Podcast
por: Dong, Brian, et al.
Publicado: (2023)

Rationale for combination of paclitaxel and CDK4/6 inhibitor in ovarian cancer therapy — non-mitotic mechanisms of paclitaxel
por: Smith, Elizabeth R., et al.
Publicado: (2022)

Targeting protein folding in N‐Myc‐driven medulloblastoma
por: Valinciute, Gintvile, et al.
Publicado: (2023)

PARP Inhibitors in Breast and Ovarian Cancer
por: Wang, Samuel S. Y., et al.
Publicado: (2023)

An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
por: Xu, Jing, et al.
Publicado: (2022)

A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer
por: Tian, Chenchen, et al.
Publicado: (2022)

CDK4/6 and diffuse intrinsic pontine glioma - Evaluate at diagnosis?
por: Becher, Oren J.
Publicado: (2019)

Cdk2 and Cdk4 cooperatively control the expression of Cdc2
por: Berthet, Cyril, et al.
Publicado: (2006)

New perspectives on epigenetic modifications and PARP inhibitor resistance in HR-deficient cancers
por: Bayley, Rachel, et al.
Publicado: (2023)

MEDB-80. CDK8 promotes stemness of MYC-driven medulloblastoma
por: Wang, Dong, et al.
Publicado: (2022)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”
por: Boussios, Stergios, et al.
Publicado: (2019)

Integration of PARP-inhibitors in ovarian cancer therapy
por: Pietragalla, Antonella, et al.
Publicado: (2020)

PARP Inhibitors in Ovarian Cancer: A Review
por: O’Malley, David M., et al.
Publicado: (2023)

A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas
por: Hadjadj, Djihad, et al.
Publicado: (2017)

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

Stable CDK12 Knock-Out Ovarian Cancer Cells Do Not Show Increased Sensitivity to Cisplatin and PARP Inhibitor Treatment
por: Chilà, Rosaria, et al.
Publicado: (2022)

Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial
por: De Angelis, Claudia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pgthrh1slv220l158ko8oadio6